Personalized cardiovascular medicine and drug development: Time for a new paradigm

Circulation

Volumn 125, Issue 4, 2012, Pages 638-645

  Loscalzo, Joseph ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

cardiovascular disease; pharmacogenetics; pharmacology

Indexed keywords

CARDIOVASCULAR AGENT; NEW DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; DRUG APPROVAL; DRUG INDUSTRY; DRUG INFORMATION; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HUMAN; PERSONALIZED MEDICINE; PHARMACEUTICAL CARE; PRIORITY JOURNAL;

CARDIOLOGY; DRUG DISCOVERY; HEART DISEASES; HUMANS; INDIVIDUALIZED MEDICINE; RISK FACTORS;

EID: 84856905738     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.089243     Document Type: Article

References (14)

1. Weiss S. Routine Practices: Medical Service of the Peter Bent Brigham Hospital. Boston, MA: Self-published; 1940:143-145.
2. Ridley M. Drugs that are as smart as our diseases. The Wall Street Journal. September 17, 2011.
3. Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Disc. 2011;10:428-438.
4. Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Disc. 2011;10:507-519.
5. Loscalzo J. Homocysteine trials-clear outcomes for complex reasons. N Engl J Med. 2006;354:1629-1632.
6. Morel NM, Holland JM, van der Greef J, Marple EW, Clish C, Loscalzo J, Naylor S. Primer on medical genomics, XIV: introduction to systems biology-a new approach to understanding disease and treatment. Mayo Clin Proc. 2004;79:651-658. (Pubitemid 38580172)
7. Loscalzo J, Kohane I, Barabasi AL. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol Syst Biol. 2007;3:124.
8. Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J. Harrison's Principles of Internal Medicine. 18th ed. New York, NY: McGraw-Hill Professional; 2012.
9. Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12:56-58.
10. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science. 2008;321:263-266. (Pubitemid 351989100)
11. Xie L, Li J, Xie L, Bourne PE. Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS Comput Biol. 2009; 5:e1000387.
12. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29: 3085-3096.
13. Liu YY, Slotine JJ, Barabasi AL. Controllability of complex networks. Nature. 2011;473:167-173.
14. Schadt EE, Friend SH, Shaywitz DA. A network view of disease and compound screening. Nat Rev Drug Disc. 2009;8:286-295.